Article
Biophysics
Ru Cheng, Fu Zhu, Min Huang, Qiang Zhang, Hui Hong Yan, Xiao Hui Zhao, Fu Kang Luo, Chun Mei Li, Hui Liu, Gao Lin Liang, Cheng Zhi Huang, Jian Wang
Summary: In this study, a new biosensor named hepatitis virus indicator was developed for the simultaneous detection of HBV and HCV. The biosensor utilized Exo III assisted signal amplification strategy and particle counting technology with a dark-field microscopy, enabling sensitive and selective detection.
BIOSENSORS & BIOELECTRONICS
(2022)
Article
Pharmacology & Pharmacy
Xia Tang, Wenxun Huang, Juan Kang, Keyue Ding
Summary: Telbivudine treatment in chronic HBV patients led to significant differences in viral quasispecies, with a reduced dN/dS ratio indicating selective constraints from antiviral therapy. Evolution patterns and resistant mutations in the quasispecies varied over a short-term treatment course.
ANTIVIRAL RESEARCH
(2021)
Review
Biochemistry & Molecular Biology
Wanting Shi, Kang Li, Yonghong Zhang
Summary: Viral hepatitis, primarily caused by HBV and HCV, is a global health concern. Delayed diagnosis and treatment can lead to liver damage and the development of cirrhosis. Traditional methods have limitations in detecting viral presence, while the use of nanomaterials has advanced virus detection technologies.
Article
Infectious Diseases
Daniel Bradshaw, David F. Bibby, Carmen F. Manso, Renata Piorkowska, Hodan Mohamed, Juan Ledesma, Laura Bubba, Yuen T. Chan, Siew Lin Ngui, Simon Carne, Jean L. Mbisa
Summary: This study evaluated a genotype-agnostic next-generation sequencing pipeline for hepatitis C virus (HCV) whole-genome analysis. The pipeline showed high concordance with Sanger sequencing and was able to detect novel subtypes, mixtures, recombinants, and resistance mutations. It has important clinical applications in settings without universal access to pan-genotypic antiviral regimens, rare subtypes, treatment failures, and suspected re-infections.
CLINICAL MICROBIOLOGY AND INFECTION
(2022)
Article
Public, Environmental & Occupational Health
Alkhansa Alshabi, Nuzhath Fatima, Amany Marwan, Khadejh G. Oraibi, Ebtihal A. Qubaisi, Hanan O. Arif, Elham M. Daghriri, Noran A. Zelai, Imran Ali Khan
Summary: The study investigated HBV infection and HBsAg genotype distribution in southwestern Jizan city, Saudi Arabia, finding a high prevalence of HBV in the region. Most participants were of Saudi nationality and the majority had genotype-D.
JOURNAL OF INFECTION AND PUBLIC HEALTH
(2021)
Article
Hematology
Mihir Gupta, Evan J. Burns, Nicholas Z. Georgantas, Julia Thierauf, Naema Nayyar, Amanda Gordon, SooAe S. Jones, Michelle Pisapia, Ying Sun, Ryan P. Burns, Jose Velarde, Justin T. Jordan, Matthew J. Frigault, Brian V. Nahed, Pamela S. Jones, Fred G. Barker, William T. Curry, Rajiv Gupta, Tracy T. Batchelor, Javier M. Romero, Priscilla K. Brastianos, Hetal D. Marble, Maria Martinez-Lage, Kensuke Tateishi, Jochen K. Lennerz, Jorg Dietrich, Daniel P. Cahill, Bob S. Carter, Ganesh M. Shankar
Summary: Diagnosing PCNSL often requires neurosurgical biopsy due to low yield of CSF studies. A multiplexed genotyping assay was designed to facilitate rapid and accurate diagnosis of PCNSL. This targeted genotyping approach helps reduce diagnostic and treatment delays in PCNSL.
Article
Immunology
Jade Pattyn, Greet Hendrickx, Alex Vorsters, Pierre Van Damme
Summary: The coverage of hepatitis B vaccines is increasing, and the effective implementation of vaccination programs has significantly reduced the morbidity and mortality related to hepatitis B.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Biophysics
Suchanat Boonkaew, Abdulhadee Yakoh, Nattaya Chuaypen, Pisit Tangkijvanich, Sirirat Rengpipat, Weena Siangproh, Orawon Chailapakul
Summary: Electrochemical paper-based analytical devices (ePADs) are simple, portable, and low-cost analytical devices for point-of-care testing of clinical biomarkers. A sequential ePAD has been developed for simultaneous detection of hepatitis B surface antigen and hepatitis C core antigen by integrating dual flow behaviors, avoiding the need for complex multi-step reagent manipulation by the user. The proposed ePAD shows high promise as an easy-to-use, portable, and extendable sensor for other multiplex biological assays.
BIOSENSORS & BIOELECTRONICS
(2021)
Article
Microbiology
Hao Wang, Fenfang Liao, Junmo Xie, Wenbo Gao, Min Wang, Jieting Huang, Ru Xu, Qiao Liao, Zhengang Shan, Yourong Zheng, Xia Rong, Chengyao Li, Yongshui Fu
Summary: The study revealed that E2G/A/V/D mutations significantly influence the detection of HBsAg, with different underlying mechanisms for OBI caused by E2 mutations in genotype B and genotype C. Additionally, E2G/A mutations may result in a N-terminal truncated S protein, contributing to HBsAg secretion impairment in OBI.
FRONTIERS IN MICROBIOLOGY
(2021)
Article
Gastroenterology & Hepatology
Wenshi Wang, Florian A. Lempp, Franziska Schlund, Lisa Walter, Charlotte C. Decker, Zhenfeng Zhang, Yi Ni, Stephan Urban
Summary: Research has shown that HDVs from different genotypes replicate with varying efficacies. Variations in HDV genomes and HBV envelope proteins are major determinants of HDV egress and entry efficacy.
JOURNAL OF HEPATOLOGY
(2021)
Article
Microbiology
Danny Ka-Ho Wong, Claire Chen, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen
Summary: This study evaluated the performance characteristics of a sensitive HBsAg assay (NEXT) and found that it demonstrated higher sensitivity compared to conventional assays, leading to an increased detection rate in patients with OBI. It can help identify HBV carriers and prevent HBV transmission and reactivation associated with OBI.
JOURNAL OF CLINICAL MICROBIOLOGY
(2022)
Article
Chemistry, Analytical
Yu Tao, Ke Yi, Haixia Wang, Kai Li, Mingqiang Li
Summary: In this study, a novel and sensitive fluorescent biosensor based on CRISPR-Cas12a enzymes and metal nanoclusters was developed for rapid and sensitive detection of HBV. The method showed higher sensitivity and faster fluorescence response compared to traditional methods, and it did not require sophisticated equipment or harsh reaction conditions. The practical application of this method in detecting HBV DNA in human serum samples was also demonstrated with satisfactory results.
SENSORS AND ACTUATORS B-CHEMICAL
(2022)
Article
Polymer Science
Boris Shaskolskiy, Ilya Kandinov, Dmitry Kravtsov, Alexandra Vinokurova, Sofya Gorshkova, Marina Filippova, Alexey Kubanov, Victoria Solomka, Dmitry Deryabin, Ekaterina Dementieva, Dmitry Gryadunov
Summary: A multiplex assay using a low-density hydrogel microarray is developed to identify genomic substitutions in N. gonorrhoeae determining resistance to treatment agents. The microarray accurately identifies drug resistance determinants and single-nucleotide substitutions, with results consistent with Sanger sequencing. Analysis of clinical isolates in Russia over 5 years demonstrates the utility of hydrogel microarrays in monitoring antibiotic resistance spread.
Article
Immunology
Xinyao Liu, Wuqi Qiu, Yan Liang, Wei Zhang, Qian Qiu, Xinxin Bai, Guolin Dai, Hao Ma, Hongpu Hu, Wei Zhao, Guangyu Hu
Summary: There is limited evidence on the effectiveness of hepatitis B virus (HBV) infection screening and vaccination programs in China. This study used a quasi-experimental method to evaluate a community-based HBV infection detection combined with vaccination (HBVIDV) program. The results showed that the program significantly increased the hepatitis B vaccination rate, vaccine series completion rate, and prevalence of vaccine-mediated immunity among adults, especially those aged 35-54 and living in rural areas.
Article
Medicine, Research & Experimental
Yinghua Yuan, Xiaojin Yang, Desheng Xie
Summary: The study identified abnormal expression of circRNAs in HBV-positive liver cancer cells, with hsa_circ_0066966 potentially regulating the progression of HBV-positive liver cancer.
EXPERIMENTAL AND THERAPEUTIC MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Silvia Chang, Charlotte Hedskog, Bandita Parhy, Ross Martin, Hongmei Mo, Evguenia Maiorova, Fabien Zoulim
Summary: Antiviral nucleos(t)ide analogue therapies can inhibit HBV replication and reduce HBV DNA levels, but HBV RNA levels may remain high. HBV RNA can be used as a viral biomarker for treatment outcome and disease progression. This study characterized the sequence of extracellular HBV RNA in plasma samples of patients with chronic HBV infection, and found that it closely resembles HBV DNA sequence. Additionally, RNA splice forms, different polyA tails start positions, and HBV-human chimeric transcript were identified.
JOURNAL OF VIRAL HEPATITIS
(2023)
Article
Gastroenterology & Hepatology
Julie Lucifora, Dulce Alfaiate, Caroline Pons, Maud Michelet, Ricardo Ramirez, Floriane Fusil, Fouzia Amirache, Axel Rossi, Anne-Flore Legrand, Emilie Charles, Serena Vegna, Rayan Farhat, Michel Rivoire, Guillaume Passot, Nicolas Gadot, Barbara Testoni, Charlotte Bach, Thomas F. Baumert, Anastasia Hyrina, Rudolf K. Beran, Fabien Zoulim, Andre Boonstra, Hildegard Buening, Eloi R. Verrier, Francois-Loic Cosset, Simon P. Fletcher, Anna Salvetti, David Durantel
Summary: This study elucidates the molecular mechanisms underlying how HDV interferes with HBV in patients with chronic coinfection. The researchers found that HDV induces the expression of interferon-stimulated genes (ISGs), and these genes are upregulated in HDV/HBV-coinfected patients. Inhibiting the hepatocyte's response to interferon partially restores the levels of HBV.
JOURNAL OF HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Pierre Nahon, Jessica Bamba-Funck, Richard Layese, Eric Trepo, Jessica Zucman-Rossi, Carole Cagnot, Nathalie Ganne-Carrie, Cendrine Chaffaut, Erwan Guyot, Marianne Ziol, Angela Sutton, Etienne Audureau
Summary: This study evaluated the ability of single nucleotide polymorphisms (SNPs) to refine hepatocellular carcinoma (HCC) risk stratification. Several genetic variants affecting lipid turnover and the Wnt-I3-β-catenin pathway were found to be associated with HCC occurrence. Incorporating these genetic variants into clinical scores improved their predictive performance for HCC.
JOURNAL OF HEPATOLOGY
(2023)
Review
Gastroenterology & Hepatology
Seng Gee Lim, Thomas F. Baumert, Carolina Boni, Ed Gane, Massimo Levrero, Anna S. Lok, Mala K. Maini, Norah A. Terrault, Fabien Zoulim
Summary: Functional cure of chronic hepatitis B (CHB), achieved through hepatitis B surface antigen (HBsAg) loss after 24 weeks off therapy, is the goal of current treatment. However, the rarity of achieving this cure with current therapy highlights the need for novel approaches. The three categories of treatment include reducing viral replication, reducing antigen load, and immunotherapies. Combination therapy of nucleos(t)ide analogues and immunotherapy shows promise in reducing HBsAg levels and inducing HBsAg loss in some patients, particularly those with low baseline HBsAg levels. Monitoring during therapy using viral and immunological biomarkers is important to predict HBsAg loss and understand its mechanisms.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
(2023)
Review
Virology
Nadjet Lebsir, Fabien Zoulim, Boyan Grigorov
Summary: Heparanase-1 is an important enzyme involved in viral infections and cancer, and its inhibitors can be used as both anti-cancer drugs and antiviral agents, potentially solving drug resistance issues in current antiretroviral therapies.
Article
Gastroenterology & Hepatology
Maria Paola Anolli, Elisabetta Degasperi, Lena Allweiss, Angelo Sangiovanni, Marco Maggioni, Caroline Scholtes, Valerie Oberhardt, Christoph Neumann-Haefelin, Maura Dandri, Fabien Zoulim, Pietro Lampertico
Summary: Bulevirtide has received conditional approval from the EMA for treating chronic hepatitis delta, but the optimal duration of therapy remains unknown. In this study, a patient with compensated cirrhosis and esophageal varices achieved hepatitis delta cure after 3 years of bulevirtide monotherapy. Virological and biochemical responses were maintained during the 72-week off-therapy follow-up, and significant improvements were observed in liver biopsy results.
JOURNAL OF HEPATOLOGY
(2023)
Article
Physiology
Arnaud Riff, Muzhda Haem Rahimi, Marie-Charlotte Delignette, Morgane Gossez, Remy Coudereau, Solene Pantel, Teresa Antonini, Francois Villeret, Fabien Zoulim, Jean-Yves Mabrut, Jerome Dumortier, Fabienne Venet, Fanny Lebosse, Guillaume Monneret
Summary: This study found that the phenotypes of neutrophils and lymphocytes, along with the expression of immune checkpoint proteins, were altered in cirrhotic patients before and after liver transplantation. These findings highlight the potential importance of immune monitoring in cirrhotic patients during liver transplantation to better assess the risk of infection.
FRONTIERS IN PHYSIOLOGY
(2023)
Article
Endocrinology & Metabolism
Cyrielle Caussy, Charlene Telliam, Bader Al-Nuaimi, Marianne Maynard-Muet, Jerome Dumortier, Fabien Zoulim, Emmanuel Disse, Cyrille Colin, Massimo Levrero, Philippe Moulin
Summary: A pathway-referral using transient elastography (TE) performed in diabetology and nutrition clinics significantly improves the liver fibrosis risk stratification and avoids over-referral. However, collaboration between diabetologists, nutritionists, and hepatologists is needed to avoid under-referral.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY
(2023)
Article
Gastroenterology & Hepatology
Sarah Duponchel, Lea Monnier, Jennifer Molle, Nadia Bendridi, Muhammad Rizwan Alam, Ahmed Gaballah, Boyan Grigorov, Alexander Ivanov, Marcel Schmiel, Margarete Odenthal, Michel Ovize, Jennifer Rieusset, Fabien Zoulim, Birke Bartosch
Summary: Chronic HCV infection causes cellular stress, fibrosis, and predisposes to hepatocarcinogenesis. Mitochondria play key roles in orchestrating stress responses. The study revealed that HCV proteins associate with mitochondria and alter the composition of mitochondrial subdomains, which are crucial for efficient viral replication.
Article
Gastroenterology & Hepatology
Milan J. Sonneveld, Shao-Ming Chiu, Jun Yong Park, Sylvia M. Brakenhoff, Apichat Kaewdech, Wai-Kay Seto, Yasuhito Tanaka, Ivana Carey, Margarita Papatheodoridi, Piero Colombatto, Florian van Boemmel, Thomas Berg, Fabien Zoulim, Sang Hoon Ahn, George N. Dalekos, Nicole S. Erler, Maurizia Brunetto, Heiner Wedemeyer, Markus Cornberg, Man-Fung Yuen, Kosh Agarwal, Andre Boonstra, Maria Buti, Teerha Piratvisuth, George Papatheodoridis, Chien-Hung Chen, Benjamin Maasoumy, Create Study Grp
Summary: This study investigated the association between pretreatment HBV DNA levels and outcomes after therapy cessation in patients with chronic hepatitis B. It was found that lower pretreatment HBV DNA levels were associated with a lower risk of clinical relapse and a higher chance of HBsAg loss after cessation of NUC therapy. These findings can help select patients for treatment withdrawal and guide intensity of off-treatment monitoring.
Article
Gastroenterology & Hepatology
Francois Vileret, Fanny Lebosse, Sylvie Radenne, Didier Samuel, Bruno Roche, Jean-Yves Mabrut, Vincent Leroy, Georges-Philippe Pageaux, Rodolphe Anty, Sylvie Thevenon, Sinafa Si Ahmed, Aaron Hamilton, Marintha Heil, Caroline Scholtes, Massimo Levrero, Barbara Testoni, Fabien Zoulim, ECOGREFFE Study Grp
Summary: This study found that viral recurrence can occur rapidly after liver transplantation, despite prophylaxis with nucleos(t)ide analogues (NUCs) and hepatitis B immunoglobulin (HBIG). The majority of patients had at least one HBV marker detected in either serum or the liver 12 months after transplantation. Optimal patient compliance to antiviral prophylaxis is crucial to prevent viral rebound.
Article
Pharmacology & Pharmacy
Thierry Verbinnen, Willem Talloen, Harry L. A. Janssen, Fabien Zoulim, Umesh Shukla, Joris J. Vandenbossche, Michael Biermer, Sandra De Meyer, Oliver Lenz
Summary: The study investigates the viral mutations in patients with hepatitis B virus infection treated with JNJ-56136379. The results demonstrate that viral breakthroughs and emergence of drug-resistant variants occurred during JNJ-56136379 monotherapy. However, the addition of nucleos(t)ide analogue treatment effectively controlled the viral mutations. This suggests that JNJ-56136379 monotherapy may not be suitable for patients with hepatitis B.
ANTIVIRAL RESEARCH
(2023)
Article
Gastroenterology & Hepatology
Jordan J. Feld, Anna S. Lok, Fabien Zoulim
Summary: Current therapy for chronic hepatitis B rarely achieves a functional cure, but novel treatments are being developed. Understanding the mechanisms of hepatitis B virus persistence has helped identify new treatment targets and evaluate novel agents in clinical trials. Combining different agents appears to be a promising strategy to reduce viral replication, invigorate immune responses, and induce specific adaptive immune responses.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Infectious Diseases
Lorin Begre, Anders Boyd, Luisa Salazar-Vizcaya, Franziska Suter-Riniker, Charles Beguelin, Juergen K. Rockstroh, Huldrych F. Guenthard, Alexandra Calmy, Matthias Cavassini, Marcel Stoeckle, Patrick Schmid, Enos Bernasconi, Massimo Levrero, Fabien Zoulim, Gilles Wandeler, Andri Rauch, Swiss HIV Cohort Study SHCS
Summary: In HIV patients with HBsAg loss, qHBsAg levels decline rapidly at the beginning and then show diverse trajectories during long-term tenofovir therapy. In patients without HBsAg loss, qHBsAg levels remain relatively stable over time.
Article
Gastroenterology & Hepatology
Man-Fung Yuen, Tarik Asselah, Ira M. Jacobson, Maurizia Rossana Brunetto, Harry L. A. Janssen, Tetsuo Takehara, Jin Lin Hou, Thomas N. Kakuda, Tom Lambrecht, Maria Beumont, Ronald Kalmeijer, Carine Guinard-Azadian, Cristiana Mayer, John Jezorwski, Thierry Verbinnen, Oliver Lenz, Umesh Shukla, Michael Biermer
Summary: This study evaluated the efficacy and safety of JNJ-73763989 (JNJ-3989) and JNJ-56136379 (JNJ-6379) in combination with nucleos(t)ide analogues for the treatment of chronic hepatitis B. The results showed that a higher proportion of patients in the JNJ-3989 dual and triple groups met the nucleos(t)ide analogue-stopping criteria at 48 weeks, with good safety profile.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)